Two scientific experiences – describing them as large – showed that decades have been common for decades for heart attacks even with modern treatments that can prevent permanent damage to the heart muscle.
It is not yet clear whether all patients, or some of them, are only benefiting from the so -called beta receptor blockers, which are usually prescribed after anyone has a heart attack.
Conflict corners were shown on a severe contrast to a major heart disease conference in Madrid, and they were published in the New England Medical Journal.
“It is not uncommon for experiments to result from various results,” said doctor Borja Eibanith of the National Carlos Center for Cardiovascular Research in Madrid, who led one of the two experiences.
“It is not very common to see two experiences with two different results, clearly exposed to the same day,” he added.
Eibaanith said that the most important thing is the result agreed upon by the two teams, which is that beta blockers reduce the risk of another heart attack, heart failure, or the risk of the death of patients who do not suffer from heart failure, but they have a slight weakness in the heart function.
A question arises: Was these pills useful or not for people with hearts that work normally, and they constitute about 80% of patients after the first heart attack?
Among the companies that produce beta blockers are: Mylan, Novarts and Fayezer.
Ephenvin and Nurabinvin
These medications work by inhibiting the hormonal Ebinverine and Norapinefrin, which reduces the heart rate and blood pressure, reduces the burden on the heart and reduces its oxygen needs.
Both new experiences included survivors of heart attacks whose hearts are still normal, that is, the left ventricle pumps at least 40% of the blood with each pulse. Both experiences followed the patients for about 3 and a half years.
The Petami-Adanlock study included 5574 volunteers from Norway and Denmark, and medications showed a clear benefit. The researchers found that patients – who were randomly chosen to receive beta -blockers – have decreased the risk of their death or their heart problems by 15%, especially the repeat of the heart attack, compared to those who did not take these pills.
But among the 8438 participants in the Reepe Dynic experience in Italy and Spain, Beta receptors blockers had no effect on the death of any cause, the repetition of a heart attack, or the hospital’s entry due to heart failure.
The researchers reported at the European Heart Journal that among the participants in the Reyboot experiment, who had to take beta receptors, especially those with good heart functions and receiving higher doses, more counter -results than those who did not take medicines.
In Ripot, the researchers noticed a decrease between 40 and 49% of the rate of new heart attacks, heart failure, or death with patients with slight weakness in the heart function of beta receptors.
Eibaanith said the message addressed to the cardiologists that “we can now say with confidence that the bita receptors’ blockers are useful” for patients with a slight weakness in the heart function.
“There is still a logical lack of certainty about its usefulness,” for patients whose hearts work normally.